2026 Call for Papers and Posters
The system will close at 4:00 pm Eastern Time (3:00 pm Central Time; 2:00 pm Mountain Time; 1:00 pm Pacific Time) on Thursday, December 18, 2025. The deadline will not be extended.
General Information Regarding Paper & Poster Abstracts
The ASPHO Conference Planning Committee invites the submission of abstracts for papers and posters to be presented at the 2026 ASPHO Conference, April 29 - May 2, in Minneapolis, MN. The conference will occur in-person, and all abstract presenters will be expected to deliver their paper or poster presentation in-person live in Minneapolis, MN.
The Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) will also be holding an educational program in conjunction with the 2026 ASPHO Conference on Tuesday, April 28, 2026. PTCTC's posters will be solicited through their own call found on their website at https://www.theptctc.org/. Abstracts can be submitted to one meeting or the other - not to both. The abstracts for both organizations will be published online in the Pediatric Blood & Cancer journal.
Important Information and Dates
Submission
The system will open in October and close on December 18, 2025. The system will close at 4:00 pm Eastern Time (3:00 pm Central Time; 2:00 pm Mountain Time; 1:00 pm Pacific Time) on Thursday, December 18, 2025.
The system may be slower on December 17 and 18 due to the higher volume of submissions. ASPHO is not responsible for abstracts that are not submitted by the deadline due to a slower system. Please plan accordingly.
Fee
There will be a $30.00 USD non-refundable fee per abstract to be paid by credit card through PayPal. The fee will be collected at the end of the submission process, before the abstract can be submitted. Payment must be done online within the system during the time of submission (payment will not be taken in any other form such as by phone or check). NOTE: Your submission will not be considered 'complete' until the payment is processed and the proposal is submitted, so please take this step into consideration when you submit your proposal.
Notification
The abstract submitter will receive notification of the committee’s decision by March 16, 2026.
Instructions for Online Abstract Submission
The goal of the ASPHO Conference Planning Committee is to solicit the very best, original basic, clinical, and social science abstracts that relate to the field of pediatric hematology and oncology. An abstract may be part of an on-going project if there are results. Abstracts previously presented or published at another conference may be submitted to ASPHO. However, these abstracts must be updated or modified in some way.
ASPHO has allowed previously presented work (e.g., a platform talk presented at the ASH meeting in December of the year prior to the ASPHO spring meeting) to be presented at the ASPHO meeting. Many societies/meetings do not allow such double presentations, so authors are encouraged to verify the rules for any meeting that may occur after the ASPHO Conference. Material that has been or is expected to be published in manuscript form before the dates of the ASPHO meeting is not acceptable for presentation in either poster or paper formats.
Case Reports/Series are acceptable as abstracts. They will be graded separately from the other themes, and authors should be aware of the following:
- If it is a case report/series, the uniqueness of the case (e.g., has this ever been described before?), the relevance of the case, the treatment used, and/or the biology involved must be clearly discussed. The quality of the discussion and the uniqueness of the case are generally the primary factors in whether these abstracts are deemed acceptable for poster/paper presentation.
Important Information about Submission and Issues Related to Copyright
The submitter will be asked to sign an Abstract Submission Agreement which confirms they agree to grant ASPHO unrestricted, irrevocable, non-exclusive, royalty-free permission to publish, reproduce, and distribute the abstract in electronic and printed materials, in a searchable data base at www.aspho.org, and in PDF file. The Submitter retains the abstract's copyright, and anyone wishing to use the abstract after the ASPHO meeting will be instructed to contact the submitter for permission.
General Information
- All communication will go to the Submitter.
- Abstracts are limited to 400 words. Tables and charts will not be accepted.
- All submitters (including those who submit case reports/series) must include the following components in the body of the abstract:
- Background
- Objective
- Design/Method
- Results
- Conclusion
- Submitters must indicate the institution, city, state, and country where the research was done.
- All abstracts (including case reports/case series) must be identified by a theme/topic. This information is used for the appropriate grouping of papers and posters at the conference as well as for publication in the Pediatric Blood & Cancer Journal and on the ASPHO website.
If you are submitting a case report/series, please select accordingly
Please note: It is up to the discretion of the ASPHO Conference Planning Committee to make the final assignment regarding the abstract’s theme.- Hemostasis, Thrombosis, and Vascular Biology
- Red Cells
- General Hematology
- Leukemia/Lymphoma/Histiocyte Disorders
- Solid Tumors
- General Oncology
- Hematopoietic Stem Cell Transplantation and Cellular Therapy
- Outcomes Research
- Outcomes Research is research that describes the end result of health care practices and intervention. Examples include studies related to cost effectiveness, health status, disease burden, late effects of treatments, and quality of life.
- Quality Improvement/Patient Safety
- Quality improvement abstracts are based on improvement of health and health care. The abstracts can be related to patient safety, processes to improve outcomes such as time to antibiotics and influenza initiatives, but the abstracts need to be based on clear evidence. Mention of key terms such as Global and Smart aims, Key Drivers, and PDSA ramps need to be included as well.
- Mark whether your abstract is a case report/case series (a case report/case series is defined as a study that includes 5 or less subjects)
- All case reports must include at least some data, otherwise, the abstract will be rejected.
- Submitters should also indicate:
- If they will be applying for the ASPHO Young Investigator Award, the Early Career Travel Stipend Award, or the Advanced Practice Professional Award.
- Their preferred presentation format: oral (paper), poster, or both.
- If the abstract was accepted at any other national meetings. If the abstract was previously presented indicate:
- format: poster or oral paper,
- what meeting the abstract was presented at,
- how the abstract has been modified, and why you feel a second presentation is important.
- If you must cite a reference, please do so at the end of the abstract using the following format: author name, publication name, and year of publication (e.g., Smith, Ped Blood & Cancer, 2023).
- All accepted abstracts will be published on the ASPHO website and in the Pediatric Blood & Cancer Journal (online format) as submitted.
Please check your submission carefully before clicking the "Submit" button in the submission system.
ASPHO will not allow any changes to the abstract once the system closes on December 18, 2025.
Conference Registration Guidelines for Presenters:
Paper and poster abstracts will be presented during concurrent session time blocks throughout the Conference. Papers will be presented on Wednesday, April 29, Thursday, April 30, and Friday, May 1, and posters will be presented on Thursday, April 30 and Friday, May 1. Presentation times will be assigned at the time the abstract is accepted; authors cannot request a specific presentation date/time. Prior to submission of a paper or poster, at least one author must agree to attend the ASPHO meeting and to participate live in-person as the paper or poster presenter. Presenters are responsible for all personal expenses (e.g., travel, hotel) and for conference registration fees. ASPHO will not waive the registration fee for presenters (lectures, papers, posters, etc). Presenters are encouraged to register for the meeting and to reserve hotel accommodations as early as possible to ensure that space is available.
Policy on Commercial Support
Presentations must avoid commercialism and should conform to the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Presentations that constitute promotion and advertising will not be accepted, including pervasive or inappropriate use of logos. No company product information may be displayed or disseminated in conjunction with the presentation. If the author(s) received any funding for this research, a clear acknowledgment of support should be included at the end of the abstract (e.g., supported by a grant from ABC Pharmaceuticals). This will count toward the 400-word limit./p>
Selection Criteria
Paper and poster submissions will be reviewed and rated by members of the Conference Planning Committee who have expertise in the research or clinical area to which the submission belongs. Each submission will be reviewed for its scientific or clinical importance, ethical practice, and study design.
Frequently Asked Questions
View the FAQs for additional information or questions regarding your submission.
Notification of Acceptance or Rejection of Submissions
The submitter will be sent an email notification by March 16, 2026 on whether the abstract was accepted or rejected for presentation. If the submitter and presenting authors are different, communication will continue through the submitter. It is the responsibility of the submitter to communicate with the presenting author. The presenting author must be a co-author on the abstract.
For questions regarding the ASPHO Conference or your abstract proposal, contact ASPHO Member Services at This email address is being protected from spambots. You need JavaScript enabled to view it. or 847-375-4716.